Breaking News

Another setback for AstraZeneca

The Anglo-Swedish laboratory announced Monday that its treatment for diabetes Farxiga was not effective in treating patients with severe form of covid.

The Anglo-Swedish laboratory announced Monday that its treatment for diabetes Farxiga was not effective in treating patients with severe form of covid.

(AFP) While its vaccine Vaxzevria is still controversial, AstraZeneca suffers a new setback. His clinical trial for a treatment for covid has failed. Thus, the drug against diabetes Farxiga “has not reached a sufficient statistical level” to prevent mortality, said the group in a statement released Monday.

Carried out on 1,250 people in collaboration with the American institute specializing in cardiovascular diseases, the study aimed to measure the effects of this treatment on patients with severe forms of covid. Those with other pathologies such as hypertension, diabetes or heart disease were particularly concerned by their risk of developing complications. Full test results will be released next May

This is a new setback for AstraZeneca, whose vaccine against Covid-19 also raises many questions, in particular with possible side effects such as cases of blood clots. Even though the European Medicines Agency has estimated that the benefit / risk balance remains “positive”, some countries have set age limits.

In France, people under 55 who have received a first dose of Vaxzevria will be injected with the Moderna or Pfizer vaccine as a second dose. Belgium, for its part, has decided to limit its use to people aged 56 and over. No action has been taken in this direction in Luxembourg, where 14,190 doses must be delivered by the end of the month.


Tags

Related Articles

Back to top button
Close
Close